Sildenafil for pulmonary arterial hypertension

Future Cardiology

Volumn 2, Issue 2, 2006, Pages 137-143

  Bartolome, Sonja D ^a   Channik, Richard N ^b  

^a UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Phosphodiesterase type 5 inhibitor; Pulmonary arterial hypertension; Revatio ; Sildenafil

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMBRISENTAN; BOSENTAN; CIMETIDINE; CREATININE; CYCLIC GMP; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; ENDOTHELIN; ENDOTHELIN RECEPTOR ANTAGONIST; ILOPROST; ITRACONAZOLE; KETOCONAZOLE; NITRATE; NITRIC OXIDE; ORAL CONTRACEPTIVE AGENT; PHOSPHODIESTERASE V; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE; PROSTACYCLIN SYNTHASE; RITONAVIR; SILDENAFIL; SITAXSENTAN; TADALAFIL; UNINDEXED DRUG; UNIPROST; VARDENAFIL; WARFARIN;

ANGINA PECTORIS; ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; COLOR VISION DEFECT; CREATININE CLEARANCE; DEATH; DEMETHYLATION; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DRUG ABSORPTION; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG SELECTIVITY; DRUG TOLERABILITY; DYSPNEA; EPISTAXIS; ERECTILE DYSFUNCTION; EUROPE; EVIDENCE BASED MEDICINE; EXERCISE; FATIGUE; FLUSHING; FOOD AND DRUG ADMINISTRATION; HEADACHE; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE CONTRACTILITY; HEART RIGHT VENTRICLE FAILURE; HUMAN; HYPOTENSION; LUNG BLOOD VESSEL; LUNG HEMODYNAMICS; LUNG VASCULAR RESISTANCE; MONOTHERAPY; MYALGIA; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PULMONARY HYPERTENSION; SIDE EFFECT; SURVIVAL RATE; SYMPTOM; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; UNITED STATES; VASCULAR ENDOTHELIUM; VASODILATATION; VISUAL DISORDER; WALKING;

EID: 33646590259     PISSN: 14796678     EISSN: 17448298     Source Type: Journal    
DOI: 10.2217/14796678.2.2.137     Document Type: Article

References (29)

1. Simonneau G, Galie N, Rubin LJ et al.: Clinical classification of pulmonary hypertension. J. Am. Coll. Cardiol. 43(12 Suppl. 1), S5-S12 (2004).
2. Farber HW, Loscalzo J: Pulmonary arterial hypertension. N. Engl. J. Med. 351(16), 1655-1665 (2004).
3. Humbert M, Morrell NW, Archer SL et al.: Cellular and molecular pathobiology of pulmonary arterial hypertension. J. Am. Coll. Cardiol. 43(12 Suppl. 1), S13-S24 (2004).
4. Tuder RM, Cool CD, Geraci MW et al.: Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am. J. Respir. Crit. Care Med. 159(6), 1925-1932 (1999).
5. Giaid A, Saleh D: Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N. Engl. J. Med. 333(4), 214-221 (1995).
6. Ghofrani HA, Pepke-Zaba J, Barbera JA et al.: Nitric oxide pathway and phosphodiesterase inhibitors in pulmonary arterial hypertension. J. Am. Coll. Cardiol. 43(12 Suppl. S), S68-S72 (2004).
7. Giaid A, Yanagisawa M, Langleben D et al.: Expression of endothelin- 1 in the lungs of patients with pulmonary hypertension. N. Engl. J. Med. 328(24), 1732-1739 (1993).
8. Rich S, Dantzker DR, Ayres SM et al.: Primary pulmonary hypertension. A national prospective study. Ann. Intern. Med. 107(2), 216-223 (1987).
9. Barst RJ, McGoon M, Torbicki A et al.: Diagnosis and differential assessment of pulmonary arterial hypertension. J. Am. Coll. Cardiol. 43(12 Suppl. 1), S40-S47 (2004).
10. McLaughlin VV, Presberg KW, Doyle RL et al.: Prognosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 126 (Suppl. 1), S78-S92 (2004).
11. Ghofrani HA, Voswinckel R, Reichenberger F et al.: Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study. J. Am. Coll. Cardiol. 44(7), 1488-1496 (2004).
12. Rybalkin SD, Yan C, Bornfeldt KE, Beavo JA: Cyclic GMP phosphodiesterases and regulation of smooth muscle function. Circ. Res. 93(4), 280-291 (2003).
13. Ahn HS, Foster M, Cable M, Pitts BJ, Sybertz EJ: Ca/CaM-stimulated and cGMP-specific phosphodiesterases in vascular and non-vascular tissues. Adv. Exp. Med. Biol. 308, 191-197 (1991).
14. Corbin JD, Francis SH, Webb DJ: Phosphodiesterase Type 5 as a pharmacologic target in erectile dysfunction. Urology 60(Suppl. 2), 4-11 (2002).
15. Revatio™ package insert. Pfizer Inc. 235 East 42nd Street, New York, NY 10017, USA.
16. Paul GA, Gibbs JS, Boobis AR, Abbas A, Wilkins MR: Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension. Br. J. Clin. Pharmacol. 60(1), 107-112 (2005).
17. Lepore JJ, Maroo A, Pereira NL et al.: Effect of sildenafil on the acute pulmonary vasodilator response to inhaled nitric oxide in adults with primary pulmonary hypertension. Am. J. Cardiol. 90(6), 677-680 (2002).
18. Ghofrani HA, Wiedemann R, Rose F et al.: Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet 360(9337), 895-900 (2002).
19. Michelakis E, Tymchak W, Lien D, Webster L, Hashimoto K, Archer S: Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide. Circulation 105(20), 2398-2403 (2002).
20. Ghofrani HA, Wiedemann R, Rose F et al.: Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. Ann. Intern. Med. 136(7), 515-522 (2002).
21. Wilkens H, Guth A, Konig J et al.: Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation 104(11), 1218-1222 (2001).
22. Leuchte HH, Schwaiblmair M, Baumgartner RA, Neurohr CF, Kolbe T, Behr J: Hemodynamic response to sildenafil, nitric oxide, and iloprost in primary pulmonary hypertension. Chest 125(2), 580-586 (2004).
23. Kothari SS, Duggal B: Chronic oral sildenafil therapy in severe pulmonary artery hypertension. Indian Heart J. 54(4), 404-409 (2002).
24. Hoeper MM, Faulenbach C, Golpon H, Winkler J, Welte T, Niedermeyer J: Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension. Eur. Respir. J. 24(6), 1007-1010 (2004).
25. Sastry BK, Narasimhan C, Reddy NK, Raju BS: Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study. J. Am. Coll. Cardiol. 43(7), 1149-1153 (2004).
26. Galie N, Ghofrani HA, Torbicki A et al.: Sildenafil citrate therapy for pulmonary arterial hypertension. N. Engl. J. Med. 353(20), 2148-2157 (2005).
27. Wilkins MR, Paul GA, Strange JW et al.: Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) study. Am. J. Respir. Crit. Care Med, 171(11), 1292-1297 (2005).
28. Ghofrani HA, Rose F, Schermuly RT et al.: Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. J. Am. Coll. Cardiol. 42(1), 158-164 (2003).
29. Galie N, Torbicki A, Barst R et al.: Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The task force on diagnosis and treatment of pulmonary arterial hypertension of the European Society of Cardiology. Eur. Heart J. 25(24), 2243-2278 (2004).